Three key details:
1. The drug, selonsertib, failed to improve NASH symptoms in the study, which took place two months after a previous study during which the drug failed. NASH is a nonalcoholic fatty liver disease that can cause fatigue, nausea and weight loss.
2. The trial involved patients with compensated cirrhosis, an advanced form of NASH.
3. In a statement, John McHutchison, chief scientific officer and head of research and development for Gilead Sciences, said: “We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease.”
More articles on gastroenterology:
4 statistics on GI workload
5 must-read articles for GI leaders
CRH posts $29M in revenue for Q1 2019 — 6 insights
